Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

rivaroxaban

Known as: 5-Chloro-N-(((5S)-2-oxo-3-(4-(3-oxomorpholin-4-yl)phenyl)- 1,3-oxazolidin-5-yl)methyl)thiophene-2-carboxamide, 5-chloro-N-(((5S)-2-oxo-3-(4-(3-oxomorpholin-4-yl)phenyl)-1,3-oxazolidin-5-yl)methyl)thiophene-2-carboxamide, Rivaroxaban [Chemical/Ingredient] 
An orally bioavailable oxazolidinone derivative and direct inhibitor of the coagulation factor Xa with anticoagulant activity. Upon oral… Expand
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2018
Review
2018
Background and Purpose— The purpose of these guidelines is to provide an up-to-date comprehensive set of recommendations for… Expand
  • table 1
  • table 2
  • table 3
  • table 4
  • table 5
Is this relevant?
Review
2018
Review
2018
The non-vitamin K antagonist oral anticoagulants (NOACs) include dabigatran, which inhibits thrombin, and apixaban, betrixaban… Expand
  • table 1
  • table 2
  • figure 1
  • table 3
Is this relevant?
Review
2018
Review
2018
Click to hear Dr Baglin's perspective on the role of the laboratory in treatment with new oral anticoagulants SUMMARY: One of the… Expand
  • table 1
  • figure 1
  • figure 2
  • table 2
Is this relevant?
Review
2017
Review
2017
OBJECTIVE To compare the efficacy, safety, and cost effectiveness of direct acting oral anticoagulants (DOACs) for patients with… Expand
  • figure 1
  • table 3
  • figure 4
Is this relevant?
Review
2017
Review
2017
Background and Purpose— Evidence from the real-world setting complements evidence coming from randomized controlled trials. We… Expand
  • figure 1
  • figure 1
  • figure 2
  • figure 2
  • figure 3
Is this relevant?
Review
2017
Review
2017
Direct oral anticoagulants (DOACs) are attractive options for treatment of heparin-induced thrombocytopenia (HIT). We report our… Expand
  • table 1
  • table 2
  • table 3
  • figure 1
Is this relevant?
Review
2017
Review
2017
BACKGROUND Chronic kidney disease (CKD) is an independent risk factor for atrial fibrillation (AF), which is more prevalent among… Expand
  • figure 1
  • figure 2
  • figure 3
  • table 1
  • table 1
Is this relevant?
Review
2017
Review
2017
BACKGROUND & AIMS: Non–vitamin K antagonist oral anticoagulants (NOACs) are convenient and effective in the prevention and… Expand
  • figure 1
  • table 1
  • table 2
  • figure 2
  • figure 3
Is this relevant?
Highly Cited
2011
Highly Cited
2011
BACKGROUND The use of warfarin reduces the rate of ischemic stroke in patients with atrial fibrillation but requires frequent… Expand
  • table 1
  • table 2
  • figure 1
  • figure 2
  • table 3
Is this relevant?
Highly Cited
2010
Highly Cited
2010
BACKGROUND Rivaroxaban, an oral factor Xa inhibitor, may provide a simple, fixed-dose regimen for treating acute deep-vein… Expand
  • figure 1
  • table 1
  • table 2
  • table 3
  • figure 2
Is this relevant?